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Background
Tumor-infiltrating lymphocytes (TILs) play a major role in
anti-tumor immune responses, and their presence is corre-
lated with survival in a variety of tumors. These TILs do
not reach the pancreatic cancer (PC) cells in significant
numbers due to the presence of stroma and a suppressive
microenvironment. Neoadjuvant chemoradiation therapy
(CRT) has been advocated as a potential way to improve
outcomes of patients with resectable or borderline resect-
able PC. More importantly, there is recent evidence to
suggest that CRT can increase the presence of TILs in the
PC microenvironment (PCME), leading to production of
interferon-g (IFN-g), which could increase the expression
of PD-L1 through a negative feedback loop. Accordingly,
we hypothesize that blocking the PD-1 receptor will syner-
gize with CRT to increase the density and activation of
TILs in the PCME.
Methods
This is a prospective multicenter randomized trial which
will accrue 45 subjects with resectable or borderline
resectable pancreatic cancer who had not received prior
treatment for PC and have ECOG of 0-1. The primary
objectives of the study are: (1) to determine the safety of
neoadjuvant CRT in combination with pembrolizumab.
(2) To estimate the difference in the number of TILs in
pancreatic cancer subjects receiving neoadjuvant CRT in
combination with pembrolizumab to the number of TILs
in subjects receiving neoadjuvant CRT alone. Eligible
subjects will be randomized 2:1 to the investigational treat-
ment (Arm A) to receive pembrolizumab administered IV
every 3 weeks on days 1, 22, and 43 during concurrent
CRT with capecitabine (825 mg/m2 orally twice daily,
Monday (M) through Friday (F), on days of radiation only)
and radiation (50.4 Gy in 28 fractions over 28 days) or
Arm B to receive only concurrent CRT with capecitabine.
In all subjects, restaging CT scan or MRI will be per-
formed at 4-6 weeks after completion of neoadjuvant
treatment to determine resectability. Patients without local
or distant disease progression will be taken to the opera-
tive room for planned surgery (within 2 weeks of imaging).
Postoperatively, resected patients will receive off study
standard of care adjuvant gemcitabine (1000mg/kg IV
weekly for 3 out of 4 weeks for 6 months). Post operatively
resected patients will be followed for up for PFS and OS
for up to 2 years. Participants are considered evaluable if
they satisfy all inclusion and exclusion criteria and have
tumor tissue samples sufficient to determine the number
of TILs. Clinical Trial Registry Number (NCT02305186).
Trial registration
ClinicalTrials.gov identifier NCT02305186.
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